

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Stephen Maxwell Taylor
Ian Alexander Shiels
Lindsay Charles Brown
Michael Whitehouse
(As Amended)

§
§
§
§

Confirmation Number: 1791

Application Number: 10/510,614
PCT Number: PCT/AU03/00415

§
§
§

Group Art Unit: Unknown

International Filing Date: 7 April 2003

§
§

Examiner: Unknown

For: USE OF C5A RECEPTOR
ANTAGONIST IN THE
TREATMENT OF FIBROSIS

§
§

Attorney Docket No: 36677.30
(formerly 4050.003000)

STATEMENT OF JOINT INVENTOR MICHAEL WHITEHOUSE

UNDER 37 C. F. R. § 1.497(d)(1)

Mail Stop PCT
Commissioner for Patents
Office of Legal Administration
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing 37 C. F. R. § 1.8 I hereby certify that this correspondence is being deposited with the U. S. Postal Service with sufficient postage as First Class Mail on the date indicated below and is addressed to: Mail Stop PCT , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313- 1450.
<u>May 3, 2006</u> Date of Deposit
<u>AUSTIN L. BROWN</u> Name of person mailing paper and fee
<u>Austin L. Brown</u> Signature of person mailing paper and fee

Sir:

I, MICHAEL WHITEHOUSE, HEREBY DECLARE AS FOLLOWS:

1. The PCT application to which the above-referenced U.S. national stage application claims priority was originally filed listing Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown, as joint inventors.

mw

2. It was determined that I, Michael Whitehouse, am also a proper joint inventor for the above-referenced U.S. national stage application.
3. I was added as a joint inventor after entry in the US national stage application by Applicants' filing a Declaration on 11 October 2005 (A copy of which is attached hereto).
4. My omission as a co-inventor of the PCT application was an inadvertent oversight, which occurred without deceptive intent on my part.
5. My omission as a co-inventor on the above-referenced U.S. national stage application, was also an inadvertent oversight, which also occurred without deceptive intent on my part.
6. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U. S. C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

7th April 2006
Date

Michael Whitehouse
Michael Whitehouse

***In re* Application of:**

§ Group Art Unit: Unknown
§
§ Examiner: Unknown
§
§ Attorney Docket No.: 36677.30
§ (formerly: 4050.003000)

International Filing Date: 7 April 2003

**For: USE OF C5A RECEPTOR ANTAGONIST
IN THE TREATMENT OF FIBROSIS**

Confirmation Number: 1791

Mail Stop PCT
Commissioner for Patents
Office of PCT Legal Administration
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing 37 C. F. R. § 1.8

I hereby certify that this correspondence is being deposited with the U. S. Postal Service with sufficient postage as First Class Mail on the date indicated below and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 3, 2006
Date of Deposit

AUTREY L BROWN
Name of person mailing paper and fee

Autrey L. Brown
Signature of person mailing paper and fee

The undersigned, Promics Pty Limited, being the assignee of record of the entire interest in the above-identified application by virtue of Assignments concurrently submitted for recordation in the U.S. Patent and Trademark Office, hereby consents to the addition of Michael Whitehouse as a joint inventor in the above-captioned patent application.

PROMICA PTY LIMITED

By: Alan Scott

Name: Alan Scott.

Title: Managing Director.

Date: April 4th 2006


Application Number: 10/510,614
PCT Number: PCT/AU03/00415

The PCT application to which the above-referenced U.S. application claims priority PCT/AU03/00415, was filed listing Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown as joint inventors. Michael Whitehouse was inadvertently omitted as a joint inventor to the PCT Application. Subsequently on entry into the U.S. national stage, the inventors for the U.S. application were identified as Stephen Maxwell Taylor, Ian Alexander Shiels, and Lindsay Charles Brown. After filing, it was also determined that Michael Whitehouse was a proper joint inventor of the U.S. application and was so identified on the Declaration.

Therefore, Applicants request the addition of Michael Whitehouse for the present application.

The required processing fee of \$130.00 is authorized to be charged to Deposit Account No. 08-1394. The Commissioner is hereby authorized to charge any further fees associated with this communication, or to credit any overpayment, to Deposit Account of Haynes and Boone, LLP Number 08-1394.

Respectfully submitted,



Mark D. Moore, Ph.D.
Registration No. 42,903

Date: 05/03/06
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 713-547-2040
Facsimile: 214-200-0853



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCTOBER 19, 2005

PTAS

500055931A

500055931A

MARK D. MOORE
901 MAIN STREET
SUITE 3100
DALLAS, TX 75202

**UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT**

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES DIVISION, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 10/19/2005

REEL/FRAME: 016658/0335
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).
DOCKET NUMBER: 36677.30

ASSIGNOR:
MAXWELL, STEPHEN TAYLOR

DOC DATE: 08/05/2005

ASSIGNOR:
SHIELDS, IAN ALEXANDER

DOC DATE: 08/05/2005

ASSIGNOR:
BROWN, LINDSAY CHARLES

DOC DATE: 08/05/2005

016658/0335 PAGE 2

ASSIGNEE:

PROMICS PTY. LIMITED
BUILDING 64, PHYSIOLOGY &
PHARMACOLOGY DEPT.
UNIVERSITY OF QUEENSLAND, ST.
LUCIA
QUEENSLAND, AUSTRALIA 4072

SERIAL NUMBER: 10510614
PATENT NUMBER:
TITLE: THERAPEUTIC METHOD

FILING DATE:
ISSUE DATE:

JEFFREY OLSEN, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

10/19/2005
500055931

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
CONVEYING PARTY DATA													
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Stephen Taylor Maxwell</td><td>08/05/2005</td></tr><tr><td>Ian Alexander Shiels</td><td>08/05/2005</td></tr><tr><td>Lindsay Charles Brown</td><td>08/05/2005</td></tr></tbody></table>		Name	Execution Date	Stephen Taylor Maxwell	08/05/2005	Ian Alexander Shiels	08/05/2005	Lindsay Charles Brown	08/05/2005				
Name	Execution Date												
Stephen Taylor Maxwell	08/05/2005												
Ian Alexander Shiels	08/05/2005												
Lindsay Charles Brown	08/05/2005												
RECEIVING PARTY DATA													
<table border="1"><tr><td>Name:</td><td>Promics Pty. Limited</td></tr><tr><td>Street Address:</td><td>Building 64, Physiology & Pharmacology Dept.</td></tr><tr><td>Internal Address:</td><td>University of Queensland, St. Lucia</td></tr><tr><td>City:</td><td>Queensland</td></tr><tr><td>State/Country:</td><td>AUSTRALIA</td></tr><tr><td>Postal Code:</td><td>4072</td></tr></table>		Name:	Promics Pty. Limited	Street Address:	Building 64, Physiology & Pharmacology Dept.	Internal Address:	University of Queensland, St. Lucia	City:	Queensland	State/Country:	AUSTRALIA	Postal Code:	4072
Name:	Promics Pty. Limited												
Street Address:	Building 64, Physiology & Pharmacology Dept.												
Internal Address:	University of Queensland, St. Lucia												
City:	Queensland												
State/Country:	AUSTRALIA												
Postal Code:	4072												
PROPERTY NUMBERS Total: 1													
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>10510614</td></tr></tbody></table>		Property Type	Number	Application Number:	10510614								
Property Type	Number												
Application Number:	10510614												
CORRESPONDENCE DATA													
Fax Number: (214)200-0853 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>													
Phone: 713-547-2040													
Email: ipdocketing@haynesboone.com													
Correspondent Name: Mark D. Moore													
Address Line 1: 901 Main Street													
Address Line 2: Suite 3100													
Address Line 4: Dallas, TEXAS 75202													
ATTORNEY DOCKET NUMBER:	36877.30												
NAME OF SUBMITTER:	Mark D. Moore												

CH \$40.00 10510614

Total Attachments: 2

source=30 executed assignment#page1.tif

source=30 executed assignment#page2.tif

PATENT
FILE NO. 36677.30 (4050.003000)

ASSIGNMENT

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, the undersigned, do hereby:

SELL, ASSIGN AND TRANSFER to Promics Pty Limited (the "Assignee"), having a place of business at Building 64, Physiology & Pharmacology Dept., University of Queensland, St. Lucia, Queensland 4072, Australia, the entire right, title and interest for the United States and all foreign countries in and to any and all improvements which are disclosed in the application for United States Letters Patent, Serial No. 10/510,614 which has been filed on October 07, 2004 and is entitled "Use of CSA Receptor Antagonist in the Treatment of Fibrosis", such application and all divisional, continuing, substitute, renewal, reissue and all other applications for patent which have been or shall be filed in the United States and all foreign countries on any of such improvements; all original and reissued patents which have been or shall be issued in the United States and all foreign countries on such improvements; and specifically including the right to file foreign applications under the provisions of any convention or treaty and claim priority based on such application in the United States;

AUTHORIZE AND REQUEST the issuing authority to issue any and all United States and foreign patents granted on such improvements to the Assignee;

WARRANT AND COVENANT that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned, and that the full right to convey the same as herein expressed is possessed by the undersigned;

COVENANT, when requested and at the expense of the Assignee, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all such improvements; execute all rightful oaths, declarations, assignments, powers of attorney and other papers; communicate to the Assignee all facts known to the undersigned relating to such improvements and the history thereof; and generally do everything possible which the Assignee shall consider desirable for vesting title to such improvements in the Assignee, and for securing, maintaining and enforcing proper patent protection for such improvements;

TO BE BINDING on the heirs, assigns, representatives and successors of the undersigned and extend to the successors, assigns and nominees of the Assignee.

Signature: _____

Name: Stephen Maxwell Taylor

Date: _____

5th August 2005

Witness' Signature: _____

Name: _____

J. J. COSTELLO

Date: _____

5th August 2005